PHILADELPHIA and OXFORD, United Kingdom, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present three posters at the 2016 SITC annual meeting. The posters summarize: (1) preclinical data from Adaptimmune's wholly-owned MAGE-A4 SPEAR™ (Specific Peptide Enhanced Affinity Receptor) T-cell therapy, (2) preclinical data from the Company's second generation SPEAR T-cell engineered to overcome immunosuppression in the tumor microenvironment, and (3) a single-patient case study from the Company's ongoing synovial sarcoma study. The 2016 SITC annual meeting will take place at the Gaylord National Hotel & Convention Center in National Harbor, Maryland on November 9 through 13, 2016. Details regarding the three presentations are as follows: Friday, November 11, 2016Poster Presentation Poster number: 3Title: "Preclinical evaluation of an optimal-affinity MAGE-A4 T cell receptor for adoptive T cell therapy"Presentation Time: 12:15 - 1:30pm Location: Prince George's Exhibition Hall AB This presentation will summarize the preclinical profile for our wholly-owned SPEAR T-cell therapy targeting the MAGE-A4 cancer-germline antigen. Friday, November 11, 2016Poster Presentation Poster number: 5Title: "Engineering 2nd Generation SPEAR T-cells to overcome FACTOR-mediated immunosuppression for adoptive cell therapy"Presentation Time: 12:15 - 1:30pm Location: Prince George's Exhibition Hall AB This presentation will summarize preclinical data from Adaptimmune's first, 2 nd generation SPEAR T-cell designed to overcome tumor immunosuppression by expressing an additional factor (which will be announced the day of the presentation). Saturday, November 12, 2016Poster PresentationPoster number: 4Title: "Case Report: Specific Peptide Enhanced Affinity Receptor T-cells (SPEAR T-cells) demonstrate long-term persistence and both in vivo and ex vivo tumoricidal activity"Presentation Time: 11:45 - 1:00pm Location: Prince George's Exhibition Hall AB Data presented will be from a single-patient case study from the ongoing synovial sarcoma trial. SPEAR T-cells were profiled and phenotyped during this patient's treatment.